ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts IBRX Hot Sheet
Join SI Premium – FREE
ImmunityBio, Inc. (NASDAQ: IBRX) reported Q4 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $6.16 million.
For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Highlights Top Shopping Center REITs Ahead of Q3 Earnings
- Evercore comments on Anthropic (ANT) S-1: 'Claude Security represents the clearest n/t competitive threat to the pre-production vendors'
- NOV Inc (NOV) spreader of November and February 16 calls
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
